Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis.
To evaluate the therapeutic efficacy of ceftriaxone + vancomycin + rifampicin (CVR) in the treatment of pneumococcal meningitis caused by a multidrug-resistant strain, single-drug regimens (ceftriaxone 100 mg/kg, rifampicin 15 mg/kg, or vancomycin 20 mg/kg), double-drug regimens (ceftriaxone + vancomycin [CV] and ceftriaxone + rifampicin [CR]) and a triple-drug combination (CVR) with or without dexamethasone were compared in a rabbit meningitis model. Meningitis was induced by a highly penicillin-resistant (MIC 2 mg/l) and ceftriaxone-resistant (MIC 4 mg/l) pneumococcal strain. Final therapeutic efficacy was evaluated by the bacterial concentration at 24 h, and the bacterial killing rate was also evaluated. All combination regimens were superior to ceftriaxone or vancomycin single-drug regimens with regard to sterilisation of CSF and bacterial killing rate. Rifampicin was as effective as combination regimens. Regardless of dexamethasone, therapeutic efficacy of CVR and CR were superior to that of CV. CVR showed comparable therapeutic efficacy to CR. Data suggested that CVR would not have additional therapeutic benefit over CR during the initial 24 h of treatment.
Lee
Hyuck
H
Dong-A University, Busan, South Korea.
Song
Jae-Hoon
JH
Kim
Shin Woo
SW
Oh
Won Sup
WS
Jung
Sook In
SI
Kiem
Sungmin
S
Peck
Kyong Ran
KR
Lee
Nam Yong
NY
D000818:Animals; D002443:Ceftriaxone / Q000008:administration & dosage / Q000493:pharmacokinetics; D015169:Colony Count, Microbial; D003907:Dexamethasone / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008586:Meningitis, Pneumococcal / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D011817:Rabbits; D012293:Rifampin / Q000008:administration & dosage / Q000493:pharmacokinetics; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000302:isolation & purification; D014640:Vancomycin / Q000008:administration & dosage / Q000493:pharmacokinetics
D014640:Vancomycin; D002443:Ceftriaxone; D003907:Dexamethasone; D012293:Rifampin